Canaccord Genuity Group Forecasts Strong Price Appreciation for Artivion (NYSE:AORT) Stock

Artivion (NYSE:AORT) had its price objective hoisted by research analysts at Canaccord Genuity Group from $50.00 to $51.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target suggests a potential upside of 13.78% from the stock’s current price.

AORT has been the topic of several other reports. Stifel Nicolaus boosted their price target on Artivion from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Monday, September 29th. Citigroup reaffirmed an “outperform” rating on shares of Artivion in a report on Friday, October 10th. JMP Securities boosted their price objective on shares of Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a report on Friday, October 10th. LADENBURG THALM/SH SH downgraded Artivion from a “buy” rating to a “neutral” rating and raised their target price for the company from $32.00 to $38.80 in a research note on Wednesday, August 13th. Finally, Citizens Jmp raised their price objective on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research note on Friday. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Artivion currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.11.

Artivion Trading Down 5.6%

AORT traded down $2.68 during trading on Friday, hitting $44.82. 535,488 shares of the company’s stock were exchanged, compared to its average volume of 433,701. The stock has a 50 day moving average price of $42.42 and a 200 day moving average price of $35.25. Artivion has a 1 year low of $21.97 and a 1 year high of $47.69. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52. The firm has a market cap of $2.11 billion, a P/E ratio of -106.72 and a beta of 1.65.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The firm had revenue of $113.39 million during the quarter, compared to analysts’ expectations of $110.71 million. Artivion’s revenue for the quarter was up 18.9% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. As a group, analysts expect that Artivion will post 0.37 EPS for the current fiscal year.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Jean F. Holloway sold 10,000 shares of the stock in a transaction on Monday, August 25th. The shares were sold at an average price of $44.37, for a total transaction of $443,700.00. Following the sale, the senior vice president directly owned 172,129 shares of the company’s stock, valued at approximately $7,637,363.73. This represents a 5.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Marshall S. Stanton sold 18,200 shares of the firm’s stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $44.02, for a total transaction of $801,164.00. Following the completion of the transaction, the senior vice president owned 64,200 shares in the company, valued at approximately $2,826,084. The trade was a 22.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 74,858 shares of company stock worth $3,250,129 in the last ninety days. 7.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Artivion

Several institutional investors have recently made changes to their positions in AORT. Vanguard Group Inc. raised its position in shares of Artivion by 8.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,029,059 shares of the company’s stock worth $128,250,000 after buying an additional 232,424 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Artivion by 338.2% during the third quarter. JPMorgan Chase & Co. now owns 122,199 shares of the company’s stock worth $5,174,000 after purchasing an additional 94,312 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Artivion by 6.2% in the third quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company’s stock worth $349,000 after purchasing an additional 477 shares during the period. Public Sector Pension Investment Board lifted its position in Artivion by 23.7% in the third quarter. Public Sector Pension Investment Board now owns 161,970 shares of the company’s stock worth $6,858,000 after purchasing an additional 30,989 shares during the period. Finally, Illinois Municipal Retirement Fund increased its holdings in shares of Artivion by 4.0% in the third quarter. Illinois Municipal Retirement Fund now owns 21,535 shares of the company’s stock valued at $912,000 after buying an additional 829 shares in the last quarter. 86.37% of the stock is owned by institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.